LAT9997

Neuropathic Pain

Phase 2 (next-gen)Active; composition-of-matter patent secured

Key Facts

Indication

Neuropathic Pain

Phase

Phase 2 (next-gen)

Status

Active; composition-of-matter patent secured

Company

An Australian biotech developing first-in-class LanCL-targeting therapies for neuropathic pain, neurodegeneration, and healthy ageing.

Drug	Company	Phase	Status
Peripheral nerve pain agent	Nyrada	Preclinical	Active
NTRX-07	NeuroTherapia	Pre-clinical	Active
Neuropathic Pain Model Service	NeuroProof	Pre-clinical	Active
Sana Device for Neuropathic Pain	Sana Health	Pivotal Trial Completed	Active
Neuropathic Pain Program	VersaPeutics	Preclinical	Active
Cerebro Platform for Pain	Vonova.io	Pre-clinical	Active
ZYNPN	Zyneyro	Pre-clinical	Active
XT-150 (Preclinical)	Xalud Therapeutics	Preclinical	Active
ONO-2910	Ono Pharmaceutical	Phase 2	Active
VX-548	Vertex Pharmaceuticals	Phase 2	Active
BDT272	KYORIN Pharmaceutical	Preclinical	Active (In-licensed)
HSK16149	Haisco Pharmaceutical Group	Phase III	Active